Ashley N Brown

List of Publications by Year
in descending order

24 papers	668 citations	687363 13 h-index	642732 23 g-index
24 all docs	24 docs citations	24 times ranked	1145 citing authors

#	Article	IF	Citations
1	A sensitive electrochemical immunosensor for label-free detection of Zika-virus protein. Scientific Reports, 2018, 8, 9700.	3.3	148
2	Modeling the viral dynamics of SARS-CoV-2 infection. Mathematical Biosciences, 2020, 328, 108438.	1.9	120
3	Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy. MBio, 2015, 6, e01741-15.	4.1	60
4	Chikungunya Virus: In Vitro Response to Combination Therapy With Ribavirin and Interferon Alfa 2a. Journal of Infectious Diseases, 2016, 214, 1192-1197.	4.0	45
5	The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines. Antiviral Chemistry and Chemotherapy, 2018, 26, 204020661880758.	0.6	37
6	Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system. European Journal of Pharmaceutical Sciences, 2018, 111, 443-449.	4.0	34
7	Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	29
8	Effect of Half-Life on the Pharmacodynamic Index of Zanamivir against Influenza Virus Delineated by a Mathematical Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 1747-1753.	3.2	27
9	In Vitro System for Modeling Influenza A Virus Resistance under Drug Pressure. Antimicrobial Agents and Chemotherapy, 2010, 54, 3442-3450.	3.2	25
10	Zanamivir, at 600 Milligrams Twice Daily, Inhibits Oseltamivir-Resistant 2009 Pandemic H1N1 Influenza Virus in an In Vitro Hollow-Fiber Infection Model System. Antimicrobial Agents and Chemotherapy, 2011, 55, 1740-1746.	3.2	24
11	Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
12	Antiviral Effects of Clinically-Relevant Interferon-Î± and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM). Viruses, 2018, 10, 317.	3.3	18
13	Pharmacokinetic Determinants of Virological Response to Raltegravir in theIn VitroPharmacodynamic Hollow-Fiber Infection Model System. Antimicrobial Agents and Chemotherapy, 2015, 59, 3771-3777.	3.2	13
14	Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer. Pharmacological Research, 2017, 124, 20-33.	7.1	13
15	Pharmacodynamic Analysis of a Serine Protease Inhibitor, MK-4519, against Hepatitis C Virus Using a NovelIn VitroPharmacodynamic System. Antimicrobial Agents and Chemotherapy, 2012, 56, 1170-1181.	3.2	12
16	Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer. Frontiers in Pharmacology, 2018, 9, 403.	3.5	8
17	Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines. Microorganisms, 2021, 9, 307.	3.6	7
18	Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus. Viruses, 2021, 13, 771.	3.3	7

#	Article	IF	Citations
19	Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV). Scientific Reports, 2017, 7, 14421.	3.3	6
20	Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system. Antiviral Research, 2017, 146, 149-152.	4.1	5
21	Antiviral Activity of the PropylamylatinTM Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions. Viruses, 2021, 13, 415.	3.3	5
22	UV-4B potently inhibits replication of multiple SARS-CoV-2 strains in clinically relevant human cell lines. Frontiers in Bioscience, 2022, 27, 1.	2.1	4
23	1088. A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19). Open Forum Infectious Diseases, 2021, 8, S635-S635.	0.9	2
24	Reply to Scagnolari et al.. Journal of Infectious Diseases, 2016, 215, jiw580.	4.0	0